Nucleic Acid Polymers are Effective in Targeting Hepatitis B Surface Antigen, but More Trials Are Needed
David Durantel∗,'Correspondence information about the author David DurantelEmail the author David Durantel
INSERM, U1052, Cancer Research Center of Lyon, Université de Lyon, Lyon, France
Tarik Asselah
Paris University, INSERM UMR 1149, Department of Hepatology, AP-HP Hôpital Beaujon, Clichy, France
DOI: https://doi.org/10.1053/j.gastro.2020.04.020
Current treatments of chronically hepatitis B virus (HBV)-infected patients, based on nucleos(t)ide analogs (NAs) and/or pegylated-interferon-alfa (PEG-IFN),1, 2, 3, 4, 5 do not lead to a high rate of hepatitis B surface antigen (HBsAg)-loss/seroconversion (<10%).6 An increased therapy-induced HBsAg-loss is currently viewed as important to achieve higher functional cure rates.7,8 This loss, likely associated with a seroconversion to anti-HBsAg antibody (HBsAb), is hypothesized as instrumental for an immune response recovery, which would ensure long-term, off-treatment, control of the infection/disease.9,10 In this issue of Gastroenterology, Bazinet et al11 report on safety and efficacy results of 48-week treatments with 2 different HBsAg-targeting nucleic acid polymers (NAPs) REP-2139-Mg or REP-2165-Mg, combined with tenofovir-disoproxil-fumarate (TDF) and PEG-IFN.作者: StephenW 时间: 2020-6-5 14:44